The first oral treatment for leishmaniasis, miltefosine, offers significant promise as it may block some target genes and components of the Nrf2 pathway, resulting in a shift in the profile of macrophages that is proinflammatory [61]. This evidence concerns the gene NFE2L2 and leishmaniasis.